Screener
Amylyx Pharmaceuticals, Inc. AMLX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $5,533 | $3,519 |
| Accrued expenses | 14,609 | 17,910 |
| Operating lease liabilities, current portion | 1,008 | 1,259 |
| Total current liabilities | 21,150 | 22,688 |
| Operating lease liabilities, net of current portion | 4,247 | 4,698 |
| Total liabilities | 25,397 | 27,386 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: |
Item 1. Financial Statements.
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s total current liabilities?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported total current liabilities of $21.15M in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s total current liabilities changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s total current liabilities decreased by 1.3% year-over-year, from $21.42M to $21.15M.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s total current liabilities?
- Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s total current liabilities has grown at a 6.9% compound annual growth rate (CAGR), from $17.4M to $22.69M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude